Interferon β adenoviral gene therapy in a patient with ovarian cancer

Daniel H. Sterman, Colin T. Gillespie, Richard G. Carroll, Christina M. Coughlin, Elaina M. Lord, Jing Sun, Andrew Haas, Adri Recio, Larry R. Kaiser, George Coukos, Carl H. June, Steven M. Albelda, Robert H. Vonderheide*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Background: A 47-year-old woman with a history of ovarian cancer and a 6-year disease-free remission presented with dyspnea and increased abdominal girth. The patient was found to have ascites and a large left pleural effusion, both of which contained malignant cells consistent with recurrent ovarian cancer. Her disease progressed despite treatment with chemotherapeutic and hormonal agents. She was then enrolled in a phase I clinical trial of adenoviral-mediated interferon β gene therapy. Investigations: Abdominal and chest CT scans, 2-[18F]fluoro- 2-deoxyglucose PET scan, viral cultures, interferon cytokine analysis, immunophenotyping, and tumor cytotoxicity analyses. Diagnosis: Stage IV ovarian cancer with malignant ascites and pleural effusion. Management: Tunneled pleural catheter and intrapleural adenoviral-mediated interferon β gene therapy.

Original languageEnglish (US)
Pages (from-to)633-639
Number of pages7
JournalNature Clinical Practice Oncology
Issue number11
StatePublished - Nov 2006

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Interferon β adenoviral gene therapy in a patient with ovarian cancer'. Together they form a unique fingerprint.

Cite this